Alvotech has entered key supply and commercialization agreements with Sandoz to expand biosimilar treatments in Canada and across Australia and New Zealand. The deal covers multiple therapeutic areas—ophthalmology, immunology, and gastroenterology—and positions both companies to broaden patient access through shared responsibilities in development, manufacturing, and distribution.

Spherix Global Insights plans to unveil a Special Topix™ report that dissects how U.S. insurers and pharmacy benefit managers will manage drug access across more than 25 disease areas. The study, due to subscribers by month’s end, promises rare, data-driven insight into formularies, contracting pressures and the post-Inflation Reduction Act landscape.